Electromed (ELMD) AI Stock Analysis

• Market Cap: $156.32M
• Dividend Yield: N/A
• Average Volume (3M): 99.41K
• Price to Earnings (P/E): 23.6
• Beta (1Y): 0.59
• Revenue Growth: 14.85%
• EPS Growth: 64.96%
• Country: US
• Employees: 174
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): 0.21
• Shares Outstanding: 8,386,115
• 10 Day Avg. Volume: 61,760
• 30 Day Avg. Volume: 99,407
• PEG Ratio: 3.53
• Price to Book (P/B): 3.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.58
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 0.63
• Enterprise Value/Gross Profit: 3.08
• Enterprise Value/Ebitda: 4.09
• 1Y Price Target: $31.33
• Price Target Upside: 68.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 70 Outperform
• Price Target: $20.00 ▲(7.30%Upside)

Electromed's strong financial performance and positive earnings call outlook are somewhat offset by bearish technical signals and a moderate valuation. The company's consistent revenue growth and profitability are significant strengths, but technical analysis indicates potential short-term challenges.

Positive Factors

Financial Health

The company has $16M in cash, $23M in accounts receivable, no debt, and is the final remaining pure-play in the HFCWO space, making it an attractive takeout target for a larger medtech strategy.

Management and Operations

The new management team and board have accomplished growth through product enhancements, sales force productivity, leaner and more efficient reimbursement, market development efforts, and streamlined operations.

Negative Factors

Market Penetration

As the Company continues to gain traction in the underpenetrated bronchiectasis market, multiple expansion is warranted.

Electromed Business Overview & Revenue Model

Company Description

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.

How the Company Makes Money

Electromed generates revenue primarily through the sales of its SmartVest Airway Clearance System and related accessories. The company sells its products directly to patients, hospitals, and other healthcare facilities, as well as through distributors. Revenue is also derived from services associated with these products, such as maintenance and support. Electromed's earnings are significantly influenced by its ability to obtain insurance reimbursements for its products, which is a crucial factor in making the products accessible to patients. The company may also engage in strategic partnerships to expand its market reach and distribution capabilities.

Electromed Financial Statement Overview

Summary

Electromed demonstrates strong financial health with robust revenue growth, high profitability, and excellent cash flow generation. The company has no debt, enhancing its financial stability and positioning it well for future growth.

Income Statement

Electromed's income statement reflects strong profitability with a TTM gross profit margin of 76.8% and a net profit margin of 11.3%. Revenue has grown robustly, increasing by 9.0% over the previous annual period, and EBIT margin is healthy at 14.5%. These metrics indicate a well-managed cost structure and operational efficiency.

Balance Sheet

The balance sheet is solid with zero total debt and a strong equity ratio of 83.4%, underscoring financial stability. Return on Equity is impressive at 15.5%, showing effective utilization of equity to generate profits. The absence of debt minimizes financial risk and enhances stability.

Cash Flow

Cash flow is exceptionally strong, with a free cash flow growth rate of 28.3% TTM and a high operating cash flow to net income ratio of 1.67, reflecting robust cash generation. The free cash flow to net income ratio of 1.64 indicates excellent liquidity and efficient cash utilization.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	61.44M	54.72M	48.07M	41.66M	35.76M	32.47M
Gross Profit	47.65M	41.73M	36.52M	31.44M	27.30M	25.20M
EBITDA	9.66M	7.42M	4.62M	3.60M	3.75M	5.86M
Net Income	7.16M	5.15M	3.17M	2.31M	2.36M	4.16M
Balance Sheet
Total Assets	52.45M	52.23M	45.81M	41.36M	37.11M	33.24M
Cash, Cash Equivalents and Short-Term Investments	15.24M	16.08M	7.37M	8.15M	11.89M	10.48M
Total Debt	0.00	87.00K	161.00K	41.00K	87.00K	81.20K
Total Liabilities	8.51M	7.69M	8.14M	7.19M	4.69M	3.00M
Stockholders Equity	43.94M	44.55M	37.67M	34.17M	32.42M	30.25M
Cash Flow
Free Cash Flow	11.92M	8.67M	-401.00K	-2.21M	2.63M	3.22M
Operating Cash Flow	12.02M	9.07M	1.31M	-686.00K	3.08M	4.20M
Investing Cash Flow	-195.00K	-395.00K	-1.72M	-1.52M	-448.00K	-977.20K
Financing Cash Flow	-8.30M	36.00K	-380.00K	-1.52M	-1.22M	-548.03K

Electromed Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELMD, the sentiment is Negative. The current price of 18.64 is below the 20-day moving average (MA) of 19.64, below the 50-day MA of 20.20, and below the 200-day MA of 25.16, indicating a bearish trend. The MACD of -0.61 indicates Positive momentum. The RSI at 42.43 is Neutral, neither overbought nor oversold. The STOCH value of 50.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELMD.

Electromed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	77 Outperform	$248.60M	20.52	9.79%	―	19.97%	17.21%
ELMD	70 Outperform	$156.32M	23.58	16.56%	―	14.85%	64.96%
SRTS	64 Neutral	$92.91M	51.41	3.46%	―	24.75%	-61.29%
SNWV	55 Neutral	$315.01M	―	0.65%	―	61.50%	34.99%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
LUNG	52 Neutral	$133.45M	―	-60.68%	―	19.84%	5.77%
INGN	51 Neutral	$182.83M	―	-14.10%	―	5.73%	72.50%

Electromed Corporate Events

Electromed Reports Strong Q3 2025 Financial Results

Electromed, Inc. reported its fiscal 2025 third-quarter results, highlighting a 13.1% increase in net revenue to $15.7 million and a 16.2% rise in operating income to $2.1 million, marking the tenth consecutive quarter of year-over-year growth. The company also announced a $5 million stock repurchase authorization and emphasized its strategic initiatives, including a Veterans Administration outreach program, which contributed to the growth in its direct homecare business, reflecting its strong market positioning and commitment to value creation for shareholders.

The most recent analyst rating on (ELMD) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Electromed stock, see the ELMD Stock Forecast page.